An integrated multimodal approach to drug repurposing in endometriosis, using ROR1 as a target
This study provides the first evidence in human-derived endometriosis models supporting rimegepant, a clinically approved calcitonin gene-related peptide antagonist with a favorable safety profile, as a potential therapy. The integrated pipeline combining molecular validation, computational prioritization, and patient-derived functional testing illustrates a translational approach to accelerate drug discovery in endometriosis.
Authors
- Caroline E. Ford (ORCID: https://orcid.org/0000-0002-4438-2309)
- Jason Anthony Abbott (ORCID: https://orcid.org/0000-0002-4406-3121)
- Nikola A. Bowden (ORCID: https://orcid.org/0000-0002-6047-1694)
- Melissa L. Holmes (ORCID: https://orcid.org/0000-0001-5894-6649)
- Kate Gunther (ORCID: https://orcid.org/0000-0003-1641-1288)
- Dongli Liu (ORCID: https://orcid.org/0000-0002-1755-8516)
- Benheng Guo
- Christine Loo
- Gill Stannard
Institutions
- Cancer Institute of New South Wales (AU)
- UNSW Sydney (AU)
- Cancer Australia (AU)
- Endometriosis UK (GB)
- Prince of Wales Hospital (AU)
- South Eastern Sydney Local Health District (AU)
- Dermatology Specialists (US)
- Australia New Zealand Gynaecological Oncology Group (AU)
- University of Newcastle Australia (AU)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-12-03
- DOI
- https://doi.org/10.3389/fphar.2025.1716062
- Primary Topic
- Endometriosis Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Australian Government